Columbus Circle Investors’s CRISPR Therapeutics CRSP Stock Holding History

Columbus Circle Investors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$8.58M	Sell	56,058 -59,468	-51%	-$7.03M	0.38%	95
2020 Q3	$9.66M	Sell	115,526 -91,579	-44%	-$8.12M	0.42%	88
2020 Q2	$15.2M	Buy	207,105 +68,194	+49%	+$3.99M	0.61%	65
2020 Q1	$5.89M	Buy	138,911 +40,023	+40%	+$2.07M	0.32%	106
2019 Q4	$6.02M	Buy	+98,888	New	+$5.4M	0.26%	117
2018 Q3	–	Sell	-47,628	Closed	-$2.8M	–	181
2018 Q2	$2.8M	Buy	+47,628	New	+$2.71M	0.06%	178

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Columbus Circle Investors's CRSP Position: Q4 2020 in Review

Columbus Circle Investors reduced its CRISPR Therapeutics (CRSP) stake by 51% in Q4 2020, selling an estimated $7.03M and leaving 56,058 shares worth $8.58M. The position accounts for 0.38% of the portfolio, ranked #95.

Columbus Circle Investors first reported a position in CRSP in Q2 2018 and has held it in 6 quarters since. The position peaked at $15.2M in Q2 2020. 412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

Columbus Circle Investors held 56,058 shares of CRISPR Therapeutics worth $8.58M as of Q4 2020.
Columbus Circle Investors sold 59,468 CRISPR Therapeutics shares in Q4 2020, an estimated $7.03M.
CRISPR Therapeutics made up 0.38% of Columbus Circle Investors's portfolio in Q4 2020, its #95 holding.
Columbus Circle Investors first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 6 quarters since.
Columbus Circle Investors's CRISPR Therapeutics position peaked at $15.2M in Q2 2020.
412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on Columbus Circle Investors's 13F filing for Q4 2020, filed 20 Jan 2021.